0GHZ.L
XSPRAY PHARMA AB (PUBL) XSPRAY
£27.85
+2.20%
2026-02-26
About XSPRAY PHARMA AB (PUBL) XSPRAY
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
Key Fundamentals
EPS (TTM)
£-5.18
ROE
-28.6%
Profit Margin
0.0%
Debt/Equity
25.97
Price/Book
1.86
Beta
-0.06
Avg Volume (10D)
764
Recent Breakout Signals
No recent breakout signals detected for 0GHZ.L.
Recent Price Range (60 Days)
60D High
£77.70
60D Low
£24.70
Avg Volume
4K
Latest Close
£27.85
Get breakout alerts for 0GHZ.L
Sign up for Breakout Scanner to receive daily notifications when 0GHZ.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
XSPRAY PHARMA AB (PUBL) XSPRAY (0GHZ.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0GHZ.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.